FDA approves Roche’s Phesgo for HER2-positive breast cancer
Roche announced that the US Food and Drug Administration (FDA) has approved Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase,…
Read More...
Read More...
